Alfasigma to Acquire Nordic Group B.V., Expanding Specialty Care Portfolio and European Presence
核心洞察
Alfasigma S.p.A. has entered a share purchase agreement with SEVER Life Sciences B.V. (搜索) to acquire 100% of Nordic Group B.V. and its subsidiaries.
The deal adds Nordic Pharma's rheumatoid arthritis (搜索) business, led by the Nordimet® methotrexate franchise, to Alfasigma's rheumatology portfolio alongside Jyseleca®.
The acquisition deepens Alfasigma's commercial reach across 18 European countries and adds platforms in Canada and Japan, bringing 265 employees and approximately €190 million in 2025 revenue.
Alfasigma S.p.A., a privately owned global pharmaceutical company headquartered in Italy, announced on August 11, 2026, that it has entered into a share purchase agreement with SEVER Life Sciences B.V. (搜索) for the sale of 100% of the shares of Nordic Group B.V. ("Nordic Pharma") and its subsidiaries. Nordic Pharma is a privately owned specialty pharmaceutical company with direct operations in Europe, Canada, and Japan.
The acquisition will add Nordic Pharma's established rheumatoid arthritis (搜索) business, led by the Nordimet® methotrexate franchise, to Alfasigma's rheumatology portfolio, which includes the Jyseleca® franchise. It will also deepen Alfasigma's commercial reach through direct operations in 18 countries across Europe and add commercial platforms in Canada and Japan. In addition to rheumatology, the acquisition includes Nordic Pharma's portfolio in women's health, critical care, and ophthalmology, and brings 265 employees with specialist capabilities and expertise.
Strategic Rationale
The transaction supports Alfasigma's M&A-led growth strategy as it actively expands its international specialty and rare disease business, with a focus on gastroenterology and immunology. It follows recent portfolio-building initiatives, including the acquisition of Jyseleca® in inflammatory diseases and the licensing agreement with GSK for linerixibat for the treatment of cholestatic pruritus associated with primary biliary cholangitis (搜索) (PBC) in adult patients.
The acquisition adds approximately €190 million in 2025 revenue. Financial terms of the transaction were not disclosed.
Executive Commentary
Francesco Balestrieri, Chief Executive Officer of Alfasigma, said: "Alfasigma is pursuing a deliberate strategy to identify the right opportunities to build our global specialty and rare disease business, focused on areas of significant unmet need in gastroenterology and immunology. The acquisition of Nordic Pharma marks a decisive step forward in that journey, strengthening our European presence and expanding our rheumatology portfolio. By combining our portfolios, scientific expertise and talented teams, we are better positioned to deliver meaningful innovation and value for patients and shareholders."
Charlotte Phelps, Chief Executive Officer of Nordic Group B.V., commented: "Alfasigma is the right partner for Nordic Pharma as we enter our next phase of growth. Both companies are patient-focused, rooted in science and entrepreneurial. We look forward to combining our experience to support patients."
Transaction Details and Company Profiles
The transaction is subject to customary closing conditions, including any required regulatory agency clearances. Following completion, SEVER Life Sciences B.V. (搜索) will continue to focus on the development of its remaining businesses, namely Sever Pharma Solutions AB, Farmaprim S.R.L., Esperante Development B.V., and Nordic Pharma Inc.
Alfasigma is a medium-sized global pharmaceutical company with offices in Bologna and Milan, distributing products in more than 100 markets worldwide and employing approximately 4,000 people. Its portfolio ranges from consumer healthcare products and primary care treatments to specialty and rare disease medications, with key therapeutic focus on gastroenterology, immunology, and vascular health.
Jyseleca® (filgotinib) is approved for use as a second-line treatment in inflammatory and autoimmune diseases including rheumatoid arthritis (搜索) and ulcerative colitis (搜索), and is marketed by Alfasigma in EU and EEA countries and in the UK. Nordic Group B.V. is headquartered in Hoofddorp, The Netherlands, with a diversified portfolio of branded and niche pharmaceutical products marketed across Europe and selected international markets.